Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02627963
Title A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors AVEO Pharmaceuticals, Inc.
Indications

renal cell carcinoma

Therapies

Sorafenib

Tivozanib

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL


No variant requirements are available.